Saul del Angel Pacheco Morales Gives Historical Review on Erythropoietin
Saul del Angel Pacheco Morales, Medical Advisor Oncology And High Specialty at Synthon México, shared on LinkedIn:
”ERYTHROPOIETIN
Erythropoietin (EPO): the treatment that changed anemia in kidney disease
For many years, people with chronic kidney disease suffered from severe anemia, extreme fatigue, and dependence on blood transfusions.
Today, this is very different, thanks to erythropoietin (EPO).
This image shows how this treatment came about:
1906 – Doctors discover that the body produces a substance that stimulates the formation of red blood cells. They exposed the serum of anemic animals to other animals and noticed an increase in red cell production.
1953–1957 – It is confirmed that the kidney is the organ that produces this substance (EPO).
1977 – Human erythropoietin is isolated for the first time.
1985 – Scientists learn how to produce EPO in the laboratory (recombinant erythropoietin).
1986–1987 – The first dialysis patients show increased hemoglobin levels and fewer transfusions.
1989 – The FDA approves EPO for treating anemia in kidney disease.
Thanks to EPO, millions of patients have been able to:
- Reduce or avoid transfusions
- Improve their quality of life
This is one of the great success stories of modern medicine and nephrology.”
Stay updated with Hemostasis Today.
-
Mar 6, 2026, 16:51Priya Reehal: Highlighting The Central Role of Nurses in Cardio-Oncology
-
Mar 6, 2026, 16:50Rainer Kaiser: Blinatumomab Shows Remarkable Response in Multi-Refractory ITP and APS
-
Mar 6, 2026, 16:18Laila Shalabi: Clopidogrel, Aspirin, and the Role of PPIs in Coronary Artery Disease
-
Mar 6, 2026, 16:17Paul McKenzie: The Value of Gene Therapy in Bleeding Disorders
-
Mar 6, 2026, 16:15Basma El Homasany: The ‘Little Brain’ of the Heart and Its Role in Health
-
Mar 6, 2026, 16:14Jamal Rana: Family History and Polygenic Risk for Coronary Heart Disease
-
Mar 6, 2026, 15:43Kristy Ainslie: Breaking Down the Discovery and FDA Approval of Drug Carriers
-
Mar 6, 2026, 15:18Claudio Laudani: Efficacy and Safety of Colchicine for Secondary Prevention in Coronary Artery Disease
-
Mar 6, 2026, 15:09Chris Simon: Persona PLUS Receives FDA Clearance for Patent‑Protected Plasma Apheresis